Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies

November 8, 2021

FLORHAM PARK, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced it is collaborating with BBK Worldwide to provide new concierge services for patients participating in its clinical studies.

Read the source article at Send Press Releases with GlobeNewswire
2021-10-25 14:16:25

Share This Story!